For your patients with migraine,

Dosing & administration for migraine

According to the American Headache Society, adherence can be affected by dosing frequency¹

Patients who are poorly adherent to a daily orally-administered drug may be more likely to adhere to a once-monthly injectable CGRP like Emgality.^1,2a

^aAt the time the American Headache Society statement was published, no oral gepant had been FDA approved for migraine prevention.¹

CGRP=calcitonin gene-related peptide.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Recommended dosing with no titration required^1a

Month 1:

Initial loading dose of 240 mg
(two 120 mg injections)

Subsequent months:

One 120 mg injection per month

^aThe Emgality Pen needle is 27 gauge x 1/2 inch.³

CGRP=calcitonin gene-related peptide.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

How to administer Emgality

Preparation⁷

• Check the pen to be sure it is not expired, damaged, cloudy, discolored, or has particles in it
• Choose an area for injection (abdomen or thigh if self-injecting or buttocks or back of upper arm if another person is injecting), being sure to choose a different site (even within an area) each month
• Clean the site with an alcohol wipe and let it dry before injecting

A simple approach: The 3 key administration steps⁷

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

Telephonic injection training and an injection how-to video are available to help guide your patients through self-administration.

Questions? Call 1-833-EMGALITY (1-833-364-2548).

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Watch how to use the Emgality Pen

Prescribing Information

Patient Information

Instructions for Use

If you or your patients have any questions about Emgality, call 1-833-EMGALITY (1-833-364-2548) to talk to a healthcare provider.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Discover how eligible patients can get Emgality for as little as $0 for up to 12 months.^a View savings cards.

^aOffer good until 12/31/2022 for up to 12 months of Emgality. Patients with commercial drug insurance may be able to pay as little as $0 for their first fill of Emgality. For the second and subsequent fills, patients must have coverage for Emgality through their commercial drug insurance plan to continue to pay as little as $0 per fill. Offer subject to a monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual savings. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

References:

1. Ailani J, Burch RC, Robbins MS; the Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;00:1-19.
2. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930-945.
3. Data on File. Lilly USA, LLC. DOF-GZ-US-0060.
4. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
5. Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; 2019.
6. Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019.
7. Emgality [Autoinjector Instructions for Use]. Indianapolis, IN: Lilly USA, LLC.